Please login to the form below
immunotherapies
This page shows the latest immunotherapies news and features for those working in and with pharma, biotech and healthcare.
Vyriad inks immunotherapy alliance with Merck/Pfizer
Vyriad inks immunotherapy alliance with Merck/Pfizer. Genetically engineered virus produces immune response in tumours. ... Merck KGaA and its avelumab partner Pfizer have agreed to test the cancer immunotherapy alongside an oncolytic virus therapy
Latest news
-
Daily brief: Novartis spends big on ezcema,
Kite has signed a deal with Netherlands-based Gadeta, a privately-held company focused on developing of novel cancer immunotherapies based on gamma delta T cell receptors (TCRs).
-
MaxCyte gets green light for solid tumour cell therapy
type of cancer immunotherapy.
-
Christina Coughlin to leave Immunocore for Tmunity
In January it raised $135m in series A to support the clinical development of its next-generation T-cell based immunotherapies, including a CRISPR-edited T-cell receptor therapy. ... H. June, MD, director of the Center for Cellular Immunotherapies at the
-
Abingworth raises $315m to expand hunt for promising biotechs
And it also helps to incubate promising biotechs, providing seed funding and office space for GammaDelta Therapeutics which last year attracted a $100m deal with Takeda for its cell-based immunotherapies
-
Pivotal data sets up Tecentriq filing in small cell lung cancer
Roche’s PD-L1 inhibitor Tecentriq has become the first cancer immunotherapy to improve survival in extensive-stage small cell lung cancer (ES-SCLC), putting it on course to end a ... These are the first positive Phase III survival results for any
More from news
Approximately 63 fully matching, plus 351 partially matching documents found.
Latest Intelligence
-
30 Women Leaders in UK Healthcare (part 2)
Officer at Immunocore (since 2013), one of the most hotly-tipped UK biotech companies in the field of immunotherapy.
-
30 Women Leaders in UK Healthcare
A very notable victory has just been announced, with Keytruda becoming the first of the groundbreaking immunotherapy drugs to exit the Cancer Drugs Fund and secure NICE approval for first-line
-
Deal Watch January 2018
Back in June 2015 Celgene and Juno announced a ten-year collaboration to combine their respective immunology expertise to develop new immunotherapies for cancer and autoimmune diseases based on T cell
-
The good, the bad and the ugly
2018 looks set to be an interesting year - coloured by the prospect of M&A, patent expiry and pricing challenges, but also invigorated by exciting advances in immunotherapy and oncology and
-
IQVIA: The High IQ Approach of Human Data Science
Therapeutic advances during that same period have been remarkable; who would have thought we’d find a cure for hepatitis C, or see immunotherapy transform outcomes in cancer care?
More from intelligence
Approximately 0 fully matching, plus 41 partially matching documents found.
Latest appointments
-
Zelluna Immunotherapy appoints chief technology officer
Zelluna Immunotherapy appoints chief technology officer. Arjan Roozen will consolidate the biotech’s manufacturing strategy. ... Norwegian biotech Zelluna Immunotherapy has bolstered its offering with the appointment of a new chief technology officer.
-
Targovax strengthens board of directors
of our novel and complementary portfolio of cancer immunotherapies.”.
-
Celgene boosts CAR-T stake again with Bluebird Bio deal
immunotherapy category.
-
Christian Pangratz to head up Sterna Biologicals
Clinical-stage immunotherapy company Sterna Biologicals has appointed its new chief executive officer in the form of Christian Pangratz, who joins the firm from Vectura Group, where he served as senior
-
Dave Lemus joins Proteros as an executive board member
Prior to his new roles, Lemus was chief operating officer and chief financial officer of Medigene, assisting in its transformation into an immunotherapy-based company through the establishment of strategic partnerships.
More from appointments
Approximately 2 fully matching, plus 41 partially matching documents found.
Latest from PMHub
-
SWITCHED ONcology Patient Experience Focus Group Full Discussion
The focus group provided deeper insight in to a number of themes including the transformation of cancer understanding, the barriers to cancer diagnosis, the advent of new treatments including immunotherapy, communication
-
Training the next generation of biotech leaders
Technology born out of barcodes, tracking and scanning will become critical as we embrace things like cellular immunotherapies. ... From dream to reality. The approval of two CAR-T therapies this year illustrates how cell and gene therapies are turning
-
SWITCHED ONcology
SWITCHED ONcology. We bring together the experts. The patients. The scientists. The technologists. The creatives. We unite powerful insights to make science mean something real. We are stronger together. We are Switched ON. Switched ONcology is the
-
The Big Communication - matching unprecedented clinical advances in immunotherapy with transformative communication
The Big Communication - matching unprecedented clinical advances in immunotherapy with transformative communication.
-
Medical information in precision medicine
Immunotherapy 2.0. Treating patients down to the molecular level of their disease is incredibly exciting. ... The immunotherapy market is hypercompetitive. In the future, the challenge will be differentiating products in this space.
More from PMHub
Approximately 12 fully matching, plus 11 partially matching documents found.
Featured jobs
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Business Unit Head, Medical Communications, London
-
Excellent package
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
Subscribe to our email news alerts
- Brexit rebels win vote on European Medicines Agency alignment
- AstraZeneca joins Merck in Brexit stockpiling effort
- NHS England to Vertex: come clean on Orkambi offer
- Moving annual total (MAT)
- Vyriad inks immunotherapy alliance with Merck/Pfizer
- J&J’s Invokana aces diabetic kidney disease trial, setting up filings
- Random42 win Creativity International Award for Scientific Animation
- Merck & Co joins big pharma pricing pledge – but sceptics unconvinced
- Aurora partners with PIPHealth and taps into patient panels
- FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics
- Allergan’s abicipar matches AMD blockbuster Lucentis in phase III
- OUTiCO growth in multi-channel creates more job openings
PMHub
Market Access Transformation
Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
